Abstract
The most common solid tumor of extra cranial in infancy, referred as neuroblastoma. Magnetic resonance imaging (MRI), ultra sound, computerized tomography scans, mIBG scan, biopsy and test for urine are used to diagnose neuroblastoma. Treatment at the younger age is beneficial because the spread of neuroblastoma cells is limited to particular part of the body. On the basis of stage of neuroblastoma before surgical removal, the tumor is shrinked chemotherapeutically. Radiotherapy is followed in certain cases for killing the left off cancer cells. About 50% of neuroblastoma is aggressive in nature and the cancer may return back despite of treating it intensively, in such cases further treatment is required. 2005-2010- The current randomization includes Metaiodobenzylguanidine therapy (mIBG).. The main factor for the determination of risk group is the stage of neuroblastoma. Age, histology and biology of tumor are considered as secondary factors for risk group determination. Metaiodobenzylguanidine (mIBG) does not completely cure neuroblastoma but is able to gain control to provide possible disease stabilization. A more highly radioactive MIBG is also used for treating advanced neuroblastoma in some children’s along with various other treatments. This therapy is also used for the treatment of refractory/ relapsed neuroblastoma. Studies were conducted and it was observed that 30-40% patients with relapsed neuroblastoma gave a positive response to mIBG therapy. I-131-MIBG acts as an active agent in treating neuroblastoma patients. No serious side effect is been noticed. Combination of MIBG along with other radio labeled agents as a component of clinical trials, such as chemotherapy to find out if these further combinations can improve cure rates.
